NCT00648219已完成1 期
Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
研究概览
简要总结
The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil 40 mg tablets to Sankyo's Benicar® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose administered under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy, adult subjects, 18 years and older
- •able to swallow medication
排除标准
- •institutionalized subjects
- •history of any significant disease
- •use of any prescription or OTC medications within 14 days of start of study
- •received any investigational products within 30 days prior to start of study
研究组 & 干预措施
1
Experimental
Olmesartan Medoxomil Tablets 40 mg
干预措施: Olmesartan Medoxomil Tablets 40 mg (Drug)
2
Active Comparator
Benicar® Tablets 40 mg
干预措施: Benicar® Tablets 40 mg (Drug)
结局指标
主要结局
The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
时间窗: blood collections through 48 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mgHealthyNCT01019590Mylan Pharmaceuticals Inc36
已完成
1 期
Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mgHealthyNCT00649623Mylan Pharmaceuticals Inc36
已完成
1 期
Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mgHealthyNCT01020214Mylan Pharmaceuticals Inc36
已完成
1 期
Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mgHealthyNCT00648661Mylan Pharmaceuticals Inc35
已完成
1 期
Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mgHealthyNCT00648804Mylan Pharmaceuticals Inc28